Skip to main content
Tessa NewsLink
Paste a health news link, or browse

No source study found

Story checked

A Newer Class of Migraine Drugs Is Linked to a 40% Rise in Miscarriage Risk : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-10-12

Short answerEvidenceSource

Short answer

No source study found

No clear answer.

We couldn't match the article's details against the peer-reviewed literature closely enough. The study may be paywalled, very new, or not indexed.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We couldn't find the study behind this story.

We couldn't match the article's details against the peer-reviewed literature closely enough. The study may be paywalled, very new, or not indexed.

Open claim evidence
3

Search result

No source study found.

We couldn't match the article's details against the peer-reviewed literature closely enough. The study may be paywalled, very new, or not indexed.

Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Related research

Research nearby

Research on this topic

Nearby papers when the source is unclear.

and 17 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 5Not checkedA newer class of injected migraine drugs, called CGRP-targeted monoclonal antibodies, may raise the risk of miscarriage in pregnancy.View evidenceHide evidence

As stated40% rise in miscarriage risk

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 5Not checkedThe article says the finding comes from new research published in JAMA Neurology and led by epidemiologist Anick Bérard of Centre Hospitalier Universitaire Sainte-Justine in Canada.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 5Not checkedThe study was observational and analyzed 7,579 pregnancies from a commercially insured US dataset, comparing exposure to anti-CGRP monoclonal antibodies or propranolol during the first 20 weeks of pregnancy or in the months before pregnancy.View evidenceHide evidence

As statedfirst 20 weeks of pregnancy; 7579 pregnancies

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 5Not checkedThe article reports that anti-CGRP monoclonal antibody exposure was associated with about a 40 percent higher chance of miscarriage, while propranolol was not associated with increased risk.View evidenceHide evidence

As statedabout 40 percent higher chance

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 5Not checkedThe article notes important caveats: the study cannot prove causation, the data come from commercially insured US records, and migraine severity, medication adherence, and pregnancy planning were not captured.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

Crossref, PubMed, Europe PMC · 17 candidate papers

And 12 more candidates considered.